Thousand Oaks Biopharma Closes $45 Million Series A Funding Round

Thousand Oaks Biopharma, a China-US CMC company that offers GMP cell culture media and biomanufacturing services, closed a $45 million Series A financing. It will use the proceeds to advance its CDMO operations and begin construction of Large Scale Cell Culture Media (LSCCM) cGMP Manufacturing facilities in Haimen, Nantong, part of greater Shanghai. The company has operations in Shanghai, Haimen, and Lanzhou, China; plus Thousand Oaks and Pleasanton, CA. The financing was led by New Alliance Capital. More details....

Share this with colleagues:

Original Article: Thousand Oaks Biopharma Closes $45 Million Series A Funding Round

More From BioPortfolio on "Thousand Oaks Biopharma Closes $45 Million Series A Funding Round"